Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dirk B. Mendel.
Antimicrobial Agents and Chemotherapy | 2002
Michael Z. Wang; Chun Y. Tai; Dirk B. Mendel
ABSTRACT Oseltamivir carboxylate is a potent and specific inhibitor of influenza neuraminidase (NA). An influenza A/H1N1 variant selected in vitro with reduced susceptibility to oseltamivir carboxylate contains a His274Tyr mutation. To understand the mechanism by which a His274Tyr mutation gives rise to drug resistance, we studied a series of NA variant proteins containing various substitutions at position 274. Replacement of His274 with larger side chain residues (Tyr or Phe) reduced the NA sensitivity to oseltamivir carboxylate. In contrast, replacement of His274 with smaller side chain residues (Gly, Asn, Ser, and Gln) resulted in enhanced or unchanged sensitivity to oseltamivir carboxylate. Previous studies have suggested that the slow-binding inhibition of NA by oseltamivir carboxylate is a result of the reorientation of Glu276. Loss of this slow-binding inhibition in the His274Tyr and His274Phe mutant NA but not in His274Asn, His274Gly, His274Ser, or His274Gln supports the conclusion that the conformational change of Glu276 is restricted in the His274Tyr and His274Phe mutant NA upon oseltamivir carboxylate binding. Interestingly, His274Asn, as well as His274Gly, His274Ser, and His274Gln, also displayed reduced sensitivity to zanamivir and its analogue, 4-amino-Neu5Ac2en. Substitution of His274 with Tyr in influenza A/Tokyo/3/67 (H3N2) recombinant NA did not affect the susceptibility to oseltamivir carboxylate. These data indicate that the volume occupied by the amino acid side chain at position 274 can influence the sensitivities of influenza N1 NA but not of N2 NA to both oseltamivir carboxylate and zanamivir.
Antiviral Chemistry & Chemotherapy | 1999
Choung U. Kim; Xiaowu Chen; Dirk B. Mendel
Influenza virus neuraminidase (NA) catalyses the cleavage of sialic acid residues terminally linked to glycoproteins and glycolipids and plays an important role in the replication of the virus. Recently, several potent NA inhibitors have been synthesized based on the rational design of mimicking the transition state of the sialic acid cleavage. Zanamivir and oseltamivir (GS 4104, the prodrug of GS 4071) have emerged as promising influenza NA inhibitors for the treatment and prophylaxis of human influenza virus infection. This review describes the recent work toward the discovery and development of influenza NA inhibitors.
Bioorganic & Medicinal Chemistry Letters | 1998
Willard Lew; Huiwei Wu; Dirk B. Mendel; Paul A. Escarpe; Xiaowu Chen; W. Graeme Laver; Bradford J. Graves; Choung U. Kim
The synthesis and influenza neuraminidase inhibitory activity of a new series of C3-aza carbocyclic neuraminidase inhibitors are described. Analogues 3c and 3j, bearing a 3-pentyl group, exhibit influenza A inhibitory activities comparable to that of 1.
Bioorganic & Medicinal Chemistry Letters | 1997
Matthew A. Williams; Willard Lew; Dirk B. Mendel; Chun Y. Tai; Paul A. Escarpe; W. Graeme Laver; Raymond C. Stevens; Choung U. Kim
Abstract The structure-activity relationships (SAR) for a new class of potent inhibitors (1) of influenza neuraminidase are described. Systematic modifications of substituents at the C-3, C-4, and C-5 positions of the carbocyclic ring were performed to establish fundamental SAR to assist in the design of potent inhibitors with activity against both of influenza A and B viruses.
Bioorganic & Medicinal Chemistry Letters | 2000
Willard Lew; Huiwei Wu; Xiaowu Chen; Bradford J. Graves; Paul A. Escarpe; Holly L MacArthur; Dirk B. Mendel; Choung U. Kim
As part of our continuing work in the area of influenza neuraminidase inhibitors, a series of C3-aza inhibitors possessing a cyclic amine side chain was synthesized and evaluated for influenza neuraminidase inhibitory activity. Analogues possessing a six-, seven- and eight-membered ring, 4c-e, respectively, at the C3 position exhibited excellent influenza B neuraminidase inhibition.
Bioorganic & Medicinal Chemistry Letters | 1999
Lijun Zhang; Matthew A. Williams; Dirk B. Mendel; Paul A. Escarpe; Xiaowu Chen; KeYu Wang; Bradford J. Graves; Geoff Lawton; Choung U. Kim
1,4,5,6-Tetrahydropyridazine derivative 15 and its C-5 epimer 19, which possessed side chains similar to GS4071, were synthesized via a hetero Diels-Alder reaction, and evaluated as influenza neuraminidase inhibitors. Compounds 15 and 19 exhibited a microM range of influenza neuraminidase inhibitory activity.
Bioorganic & Medicinal Chemistry Letters | 1997
Willard Lew; Matthew A. Williams; Dirk B. Mendel; Paul A. Escarpe; Choung U. Kim
The importance of the oxygen atom in the C3 ether side chain of a carbocyclic influenza neuraminidase inhibitor 3 was investigated by replacement of the C3 ether oxygen atom of 3 with either a sulfur atom (compound 4) or a carbon atom (compound 5). The regio- and stereospecific syntheses of both isoteres are described starting from (−)-quinic acid.
Bioorganic & Medicinal Chemistry Letters | 1997
Lijun Zhang; Matthew A. Williams; Dirk B. Mendel; Paul A. Escarpe; Choung U. Kim
The influence of C2-substitution of GS 4071 on the influenza neuraminidase inhibitory activity was investigated. The introduction of lipophilic substituents (chloro, methyl, and methylthio) at the C2 position resulted in a significant decrease of the activity. This result indicates that at the enzyme active site there is limited hydrophobic pocket for group at the C2 position of GS 4071.
Bioorganic & Medicinal Chemistry Letters | 1999
Willard Lew; Paul A. Escarpe; Dirk B. Mendel; David J. Sweeny; Choung U. Kim
The total synthesis for the determination of the absolute stereochemistry of a GS 4104 metabolite 3 is described. In addition, the influenza neuraminidase inhibitory activity of 3 and related intermediates are reported.
Journal of the American Chemical Society | 1997
Choung U. Kim; Willard Lew; Matthew A. Williams; Hongtao Liu; Lijun Zhang; S. Swaminathan; Norbert Bischofberger; Ming S. Chen; Dirk B. Mendel; Chun Y. Tai; and W. Graeme Laver; Raymond C. Stevens